Gluconite

Quick links to important sections

Gluconite

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gluconite

Quick Facts

Property Description
Active Ingredient Nitroglycerin (Glyceryl Trinitrate)
Form Sublingual tablets, oral spray, transdermal patch, IV solution
Pharmacological Class Organic Nitrate, Vasodilator
General Purpose Relief and prevention of symptoms related to insufficient oxygen supply to the heart muscle
Origin Synthetic (chemically derived)

Core Identity and Classification

Gluconite is a pharmaceutical preparation whose primary active component is Nitroglycerin, known internationally as Glyceryl Trinitrate (GTN). This medication is classified as an organic nitrate, which places it within the broader vasodilator class of pharmacological agents.

As a synthetic, single-component product derived from glycerol and nitric acid, Nitroglycerin's identity is defined by its core chemical structure. The organic nitrate category is essential to its function, defining its targeted therapeutic action in the circulatory system. Its efficacy has been clinically recognized by major health organizations for its fundamental role in managing blood flow issues.


Forms and General Purpose

The active ingredient, Nitroglycerin, is made available in several distinct dosage forms designed for various routes of administration, including sublingual tablets, oral sprays, transdermal patches, and specialized intravenous solutions. This array of pharmaceutical forms is crucial because it allows the drug to be administered via sublingual, topical, or intravenous routes, depending on the required speed of action. All forms deliver the same active agent, differing only in the vehicles used to control the rate and location of its release in the body.

The general therapeutic purpose of Gluconite is to alleviate or prevent symptoms related to reduced oxygen supply to the heart muscle by causing widespread relaxation of blood vessels (vasodilation). This powerful effect on the venous system provides the core benefit: by reducing the volume of blood returning to the heart, it substantially decreases the heart's workload and overall oxygen demand. This fundamental action is essential for the relief of discomfort associated with angina pectoris (chest pain), a condition linked to an imbalance between oxygen supply and demand in the heart muscle.

Regulatory References

  1. Nitroglycerin - StatPearls - NCBI Bookshelf

What side effects are possible with Gluconite?

Possible Side Effects and Safety Information

The safety profile for Gluconite (Nitroglycerin) is primarily defined by the consequences of its vasodilatory action, which are classified according to official regulatory standards (e.g., Very Common, Common, Uncommon) in documents such as the FDA Prescribing Information and the EMA SmPC.

Officially Documented Adverse Reactions

Adverse reactions are formally listed by the physiological system they affect. Effects on the Nervous System and Vascular System represent the most frequent occurrences. The most commonly reported event is headache, classified as Very Common (ge 1/10).

Common adverse reactions (ge 1/100 to < 1/10) officially documented include:

  • Dizziness, Syncope (fainting)
  • Hypotension (low blood pressure), Flushing
  • Tachycardia (increased heart rate)
  • Nausea and Vomiting

Serious Reactions and Safety Patterns

The regulatory profile identifies serious adverse reactions, including the potential for severe hypotension or shock and the rare, dose-related systemic risk of methemoglobinemia.

A key safety pattern noted in regulatory documentation is the relationship between exposure and occurrence: headache is explicitly stated as being most frequent during the initial phase of treatment.

Safety Constraints and Special Populations

The official labeling defines specific restrictions for use. The drug is absolutely contraindicated for co-administration with phosphodiesterase type 5 (PDE5) inhibitors due to the risk of severe, life-threatening hypotension.

Furthermore, its use is contraindicated in patients with conditions associated with increased intracranial pressure, severe anemia, and constrictive pericarditis. Caution is also noted for use in patients with severe liver or kidney impairment.

Overdose and Emergency Response

A Nitroglycerin (Gluconite) overdose is characterized by severe clinical manifestations resulting from excessive vasodilation, as documented in regulatory labeling. Officially documented signs include profound hypotension (severely low blood pressure), persistent throbbing headache, vertigo, syncope, and palpitation. Other presentations involve flushing, heavy perspiration, and potential gastrointestinal symptoms such as nausea and vomiting. Systemic signs like cyanosis and restlessness may also occur.

Severe or life-threatening outcomes officially documented in regulatory labels include circulatory collapse and the systemic condition known as methaemoglobinaemia, which compromises the blood's ability to carry oxygen. Increased intracranial pressure leading to cerebral symptoms is also recognized. Older individuals are specifically noted for an increased risk of severe hypotension and associated syncope.

Immediate medical assistance is required if an overdose is suspected or if severe symptoms develop. Specifically, the official labeling mandates that an individual seek prompt medical attention if acute symptoms, such as chest pain, have not resolved after a total of three doses (tablets or sprays). Management is primarily symptomatic and supportive, aiming to reverse hypotension through measures like elevation of the extremities and intravenous fluid administration. No specific antidote for the molecule is known; however, methylene blue is a recognized treatment for clinically significant methaemoglobinaemia.

Therapeutic Uses of Gluconite

What Gluconite Treats: Main Uses and Benefits

Gluconite (Nitroglycerin) is generally used across conditions presenting with acute or episodic manifestations of angina (chest pain) due to coronary artery disease. It is applied across domains where additional symptomatic support is needed to address symptoms related to physical discomfort and systemic imbalance. This medication is commonly used to help with acute symptom clusters that may become intense or disruptive, specifically anginal pain, tightness, or pressure in the chest.

The therapeutic benefit is often sought in conditions involving recurrent or episodic manifestations of chest discomfort and in scenarios where supportive symptom management for severe circulatory crises is appropriate. It is relevant for easing symptoms associated with angina pectoris, acute coronary syndromes, and acute heart failure exacerbations.

“This therapy is commonly used to help address symptoms related to heightened physiological activity and provides support that helps ease the overall symptom burden during symptomatic phases.”

The medication is relevant in situations where patients anticipate activities that create noticeable physiological strain, such as exercise or emotional stress. It contributes to easing discomfort during periods of heightened symptoms and may help patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Anginal Chest Discomfort

Property Description
Primary Symptom Targeted Chest pain, pressure, or tightness (Angina Pectoris)
Main Therapeutic Role Symptomatic relief and support for episodic symptom management
Acute Context Used during phases when acute symptoms become more noticeable
Prophylactic Context Applied before activities that create noticeable physiological strain

Regulatory References

  1. NIH MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Gluconite?

This section outlines the official population eligibility and prohibitions for using Gluconite (Nitroglycerin), based strictly on government regulatory documents.


Contraindicated Populations (Prohibited Use)

According to official labeling, Gluconite is absolutely contraindicated and must not be used by:

  • Patients with a known hypersensitivity to nitroglycerin or other organic nitrates.
  • Patients concurrently using Phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil) or soluble Guanylate Cyclase (sGC) stimulators (e.g., riociguat), due to the risk of severe hypotension.
  • Patients diagnosed with severe anemia or those with increased intracranial pressure (e.g., from head injury).

Age and Special Population Restrictions

Population Official Regulatory Status
Pediatric Patients Safety and effectiveness have not been established in this age group.
Adult Patients Use is established for the relief and prevention of angina pectoris.
Older Adults Dose selection should be cautious, reflecting the higher likelihood of decreased organ function.
Pregnancy/Lactation No adequate and well-controlled studies exist. Use only if clearly needed. It is not known if the drug is excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

As a dietary supplement, Gluconite does not have a formal regulatory drug label (e.g., FDA/EMA) documenting specific pharmacokinetic interactions, such as effects on CYP enzymes or drug transporters. However, the product contains botanical ingredients with known physiological activity that may interact with certain medications.

Potential Pharmacodynamic Interactions

The most commonly cited interactions are related to blood sugar management and blood clotting, stemming from ingredients like cinnamon and white willow bark.

Substance Category
Antidiabetic Medications: Ingredients that may lower blood sugar (e.g., cinnamon) can have an additive effect when combined with prescription drugs for diabetes (e.g., insulin, metformin). This may increase the risk of hypoglycemia (low blood sugar).
Anticoagulants and Antiplatelets: Components such as white willow bark and certain flower extracts (e.g., chamomile, hibiscus) may possess mild antiplatelet properties. Combining the supplement with prescription blood thinners (e.g., warfarin, clopidogrel) could increase the risk of bleeding or bruising.
Sedatives and CNS Depressants: Ingredients known for sleep support (e.g., chamomile, hops) may intensify the effects of sedative medications, including benzodiazepines or narcotics, potentially leading to increased drowsiness.

It is essential to consult a healthcare provider before combining this product with any prescription medication to manage potential additive or synergistic effects.

Mechanism of Action

Gluconite's action begins as a prodrug that requires internal conversion. It is biologically inactive until the enzyme Mitochondrial Aldehyde Dehydrogenase-2 (ALDH2) liberates Nitric Oxide (NO) within the cells of the blood vessel walls. This enzymatic bioactivation represents the initial mechanistic step, directly controlling the availability of the active molecule.

The released NO acts as an agonist, stimulating the enzyme Soluble Guanylate Cyclase (sGC). This enzyme activation rapidly increases the cellular concentration of cyclic Guanosine Monophosphate (cGMP), initiating a cascade that leads to the dephosphorylation of Myosin Light Chains. The molecular sequence results in the relaxation of vascular smooth muscle and the immediate widening of blood vessels (vasodilation), constituting the primary cellular mechanism.

The resulting vasodilation predominantly affects the venous circulation, causing venous pooling of blood. This critical hemodynamic change reduces the volume and pressure of blood returning to the heart (preload). This reduction in preload consequently decreases the workload placed on the heart muscle, resulting in a reduction in the heart's myocardial oxygen demand ( MVO2). This focused preload reduction constitutes the drug's key systemic physiological consequence.

The efficacy of the drug's mechanism is physiologically constrained by the functionality of the ALDH2 enzyme. With continuous exposure, ALDH2 can become impaired or oxidized, which limits the necessary bioactivation step. This mechanism-dependent limitation manifests as the attenuation of subsequent signaling due to reduced Nitric Oxide release, illustrating a constraint of the bioactivation step.

Dosage and Administration Information

Administration and Dosing Protocols

The usage of Gluconite (Nitroglycerin) is defined by protocols concerning the administration route, frequency, and dose limits, based on the required speed and duration of action.


Administration Routes and Forms

Nitroglycerin is provided in distinct pharmaceutical forms for sublingual, buccal, transdermal, and intravenous (IV) administration. The sublingual tablets and lingual aerosol spray are utilized when rapid onset is necessary, while the transdermal patch provides a continuous, scheduled release.

Acute and Prophylactic Regimens

Context Dose and Frequency Pattern
Acute Relief (Sublingual/Spray) 0.3 mg to 0.6 mg per dose, repeated every 5 minutes, not to exceed three total doses within a 15-minute period.
Chronic Prophylaxis (Transdermal) The patch is typically worn for 12 to 14 hours daily and must be followed by a 10 to 12 hour drug-free interval to prevent the development of pharmacological tolerance.

Procedural and Contextual Constraints

For acute sublingual use, administration occurs while the patient is resting, and the tablets must be allowed to dissolve under the tongue without being chewed or swallowed. For continuous IV infusion, the concentrated solution must be diluted prior to use. Furthermore, specific non-adsorptive administration sets must be employed to ensure the accurate delivery of the intended dosage, as Nitroglycerin may adhere to standard tubing. Dosing for older adults is generally initiated cautiously at the low end of the labeled dose range.

Recent Clinical Evidence

Research Evidence for Angina Symptoms

Research examining Gluconite (Nitroglycerin) was studied for outcomes related to chest pain symptoms in short-term randomized controlled trials and crossover studies. For acute relief, studies reported patterns of time intervals from administration until the end of patient-reported symptoms in adults with chronic stable angina.

For prevention (prophylaxis), the medication was evaluated in controlled exercise testing scenarios. Research describes the total exercise time patients could complete before experiencing symptoms, and monitored the time interval to the appearance of pain. However, studies also noted that the measured response was observed in some studies to change with continuous use, a pattern known as tolerance.

Acute and Complex Clinical Settings

Gluconite was observed in conditions such as acute coronary syndromes and severe heart failure exacerbations. The research base includes older randomized controlled trials that varied in size and subsequent retrospective studies, which examined outcomes like short-term mortality, Major Adverse Cardiac Events (MACE), and specific haemodynamic parameters. Findings were mixed when it came to outcomes such as mortality and reinfarction. Observational data show patterns related to variable outcomes in specific patient groups, such as older adults.

What is Still Uncertain

The evidence for this medicine often highlights research limitations. A significant portion of the evidence for acute use was collected during an earlier era of medical treatment. This fact means the research results apply only to the conditions and treatment landscapes that existed at the time. Furthermore, long-term effects are not fully established; the follow-up durations were limited across many trials, resulting in insufficient data for assessing the long-term impact on overall survival or durability of response. Data for specific subgroups remain insufficient for long-term outcomes.

Key Studies & References

  1. Nitroglycerin Drug Information (Initial Classification)
  2. Nitroglycerin Drug Information Overview (Main Uses and Benefits)

Frequently Asked Questions (FAQ)

Common questions about Gluconite (FAQ)


Q: How quickly does Gluconite start working after I take it?

For the sublingual tablet or spray, official information indicates a rapid onset of action. The maximum effect of the medicine typically occurs and peaks within the first few minutes after it is administered.


Q: Can I take Gluconite at night or does it have to be taken in the morning?

For the transdermal patch used for long-term prevention, protocols require a daily drug-free interval of 10 to 12 hours to prevent the body from building up tolerance. Official prescribing information does not mandate a specific time of day for this patch-free period.


Q: Are there any long-term effects of taking Gluconite regularly?

Official documents note that with continuous exposure, the body can develop tolerance, which means the drug’s effectiveness may be reduced over time. Furthermore, due to limitations in the follow-up duration of many trials, long-term effects on outcomes like overall survival have not been fully established.


Q: Will I feel different right away when I start taking Gluconite?

The medicine’s effects, such as widening blood vessels (vasodilation), can cause immediate sensations. A headache is the most commonly reported side effect, often most noticeable when treatment first begins. Flushing (redness) or temporary dizziness may also be experienced.


Q: What is the official classification of Gluconite (e.g., controlled substance)?

The official classification for Gluconite (Nitroglycerin) is an Organic Nitrate and a Vasodilator. Regulatory labeling classifies it as a prescription-only drug (Rx only) and it is not listed as a DEA-scheduled controlled substance.


Q: What are the warnings listed on the official Gluconite drug label?

The most critical warnings include the risk of severe hypotension (extremely low blood pressure). Use is contraindicated (prohibited) with certain medications, specifically those known as Phosphodiesterase-5 (PDE5) inhibitors or sGC stimulators, due to the risk of a severe drop in blood pressure.


Q: How long does it take for a potential side effect from Gluconite to go away?

The officially documented headaches, which are most common when starting therapy, usually subside with continued use as the body adjusts. Other temporary side effects, like dizziness or lightheadedness, are generally linked to the presence of the drug in the body and are transient.


Q: What are the signs of a serious, but rare, allergic reaction to Gluconite?

Serious but rare reactions noted in official documentation include the potential for severe hypotension or shock. There is also a rare risk of methemoglobinemia, whose signs can involve the skin, lips, or fingernails turning a blue or purple color.


Q: Do I need a prescription from a doctor to get Gluconite?

The official regulatory labeling states the medicine is available by prescription only (Rx only). Authorization from a qualified healthcare provider is required.


Q: Is it true that Gluconite affects sleep?

Official safety data reports drowsiness (somnolence) as one of the less common adverse reactions that have been reported for this medicine. The official documentation reports drowsiness as an adverse reaction that has been noted.


Q: Does Gluconite cause any weight changes?

Regulatory safety information includes the listing of rapid weight gain or unusual weight gain or loss in the list of less common or rare adverse reactions that have been reported with this drug.


Q: What does 'contraindication' mean when it is listed for Gluconite?

A contraindication is an essential regulatory term that describes a specific circumstance or existing condition where a medicine is officially prohibited from use. Contraindications are listed because using the drug under those circumstances is associated with a significantly increased risk of serious adverse effects.


Q: If I am taking blood pressure medicine, can I still use Gluconite?

Official label information describes that the medication may enhance the effects of other blood pressure-lowering drugs, which could lead to severe hypotension. This is a general risk warning about a potential additive effect.


Q: What happens if I stop taking Gluconite suddenly?

Studies in industrial workers exposed to high doses of related organic nitrates showed that abrupt cessation could lead to physical dependence, resulting in symptoms like chest pain. The significance of these observations for typical clinical use is not known.


Q: Does Gluconite interact with alcohol?

Official regulatory documents indicate that consuming alcohol with this medicine may increase the risk of hypotension (low blood pressure). This interaction can worsen side effects such as lightheadedness, dizziness, or fainting.


Q: Are there any common interactions with over-the-counter painkillers like ibuprofen?

Official labeling notes that the effects of this medication may be enhanced by the administration of aspirin. The drug label does not specifically address other common over-the-counter painkillers, such as ibuprofen, as a class.


Q: Does Gluconite contain lactose or gluten?

Some specific dosage forms, such as the sublingual tablets, officially contain lactose monohydrate as an inactive ingredient. Regulatory documents generally focus on active ingredients and may not confirm the presence or absence of gluten.


Q: Does taking Gluconite require regular blood tests?

The official documentation requires continuous monitoring of blood pressure and heart rate when the drug is administered intravenously in a clinical setting. However, routine blood testing is not universally mandated for all patients using oral or transdermal forms.


Q: Do the official documents list any warnings about driving or operating machinery while on Gluconite?

Official patient information advises that side effects like dizziness, lightheadedness, or fainting may affect a person’s ability to drive or operate machinery. Official documentation advises caution, noting that these effects may impair a person's ability to safely drive or operate machinery.

How should Gluconite be stored and disposed of?

How to Store and Dispose of Nitroglycerin (Gluconite)

Official regulatory labeling for Nitroglycerin, the active ingredient in Gluconite, mandates strict storage conditions.


Official Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature (20 C to 25 C).
Protection Protect from light and excessive heat. Do not refrigerate or freeze.
Packaging Must remain in the original glass container and be kept tightly closed to prevent moisture exposure.
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired medication must be handled via established drug take-back programs. The product should not be flushed down the toilet or disposed of in household waste, in alignment with environmental protection requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gluconite found in:

A-Z Index: